0
Lung Cancer |

Determinants on the Success of 2nd Line Chemotherapy in Advanced Nonoperable Non-small Cell Lung Cancer

Seok Jeong Lee*, MD; Hyun Ju Kang, MD; Yon Ju Ryu, PhD; Jin Hwa Lee, PhD; Jung Hyun Chang, PhD
Author and Funding Information

Mokdong Hospital Ewha Womans University, Seoul, Republic of Korea


Chest. 2012;142(4_MeetingAbstracts):641A. doi:10.1378/chest.1388263
Text Size: A A A
Published online

Abstract

SESSION TYPE: Lung Cancer Posters II

PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM

PURPOSE: Lung cancer has highest mortality among cancer in Korea. In advanced nonsmall cell lung cancer (NSCLC), major therapeutic modality is chemotherapy. With the progression of lung cancer, second line chemotherapy is demanded. However, there is a controversy about 2nd-line chemotherapy in terms of selection of chemotherapeutics, number of cycles, and response rates. Even numbers of clinical trials has been done for the effect of 1st-line chemotherapy, the study of 2nd-line chemotherapy is limited. The objective of this study is the analysis of determinants on the success of 2nd-line chemotherapy in advanced non-operable NSCLC.

METHODS: The patients’ records were reviewed retrospectively from 2005 to 2011 in Ewha Medical Center, Seoul, Korea. Included 87 patients were non-operable cases of stage III-IV NSCLC, received 2nd-line chemotherapy. The patients were divided into two groups: 47 subjects of successful chemotherapy, defined as more than 3 cycles (success group) and 40 subjects of unfavorable chemotherapy, defined as below 3 cycles (failure group).

RESULTS: Success in 2nd-line chemotherapy was not affected from baseline BMI, gender, smoking, albumin level, lung function, platinum based chemotherapy in 1st-line, duration of 1st-line, use of newer chemotherapeutics in 1st-line, T stage, M stage, histology of adenocarcinoma, and previous radiotherapy to lung. Only, Age and N stage were different significantly between 2 groups. Success group showed better survival (21±12mo) than failure group (13±10mo).

CONCLUSIONS: Relatively younger age and less N stage regardless of previous therapeutic condition are most important determinants on the success of 2nd-line chemotherapy, which affects to survival directly in advanced non-operable NSCLC.

CLINICAL IMPLICATIONS: Successful 2nd-line chemotherapy is very difficult in advanced lung cancer. It guides an implication of effectiveness and prognosis prior to 2nd-line chemotherapy with the consideration of age and N stage.

DISCLOSURE: The following authors have nothing to disclose: Seok Jeong Lee, Hyun Ju Kang, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang

No Product/Research Disclosure Information

Mokdong Hospital Ewha Womans University, Seoul, Republic of Korea

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543